DD273285A5 - Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung - Google Patents

Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung Download PDF

Info

Publication number
DD273285A5
DD273285A5 DD31410688A DD31410688A DD273285A5 DD 273285 A5 DD273285 A5 DD 273285A5 DD 31410688 A DD31410688 A DD 31410688A DD 31410688 A DD31410688 A DD 31410688A DD 273285 A5 DD273285 A5 DD 273285A5
Authority
DD
German Democratic Republic
Prior art keywords
leu
giu
ser
thr
ala
Prior art date
Application number
DD31410688A
Other languages
German (de)
English (en)
Inventor
Rudolf Hauptmann
Ingrid Maurer-Fogy
Gerhard Bodo
Peter Swetly
Christian Stratowa
Edgar Falkner
Guenther Adolf
Christian M P Reutelingsperger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19873710430 external-priority patent/DE3710430A1/de
Priority claimed from DE19873710364 external-priority patent/DE3710364A1/de
Priority claimed from DE19873710309 external-priority patent/DE3710309A1/de
Priority claimed from DE19873737367 external-priority patent/DE3737367A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of DD273285A5 publication Critical patent/DD273285A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721Lipocortins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
DD31410688A 1987-03-28 1988-03-28 Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung DD273285A5 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19873710430 DE3710430A1 (de) 1987-03-28 1987-03-28 Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung
DE19873710364 DE3710364A1 (de) 1987-03-28 1987-03-28 Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung
DE19873710309 DE3710309A1 (de) 1987-03-28 1987-03-28 Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung
DE19873737367 DE3737367A1 (de) 1987-11-04 1987-11-04 Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung

Publications (1)

Publication Number Publication Date
DD273285A5 true DD273285A5 (de) 1989-11-08

Family

ID=27433878

Family Applications (1)

Application Number Title Priority Date Filing Date
DD31410688A DD273285A5 (de) 1987-03-28 1988-03-28 Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung

Country Status (17)

Country Link
US (1) US5837842A (ja)
EP (1) EP0293567B1 (ja)
JP (1) JPH01503515A (ja)
KR (1) KR890700666A (ja)
AT (1) ATE133707T1 (ja)
AU (1) AU625214B2 (ja)
DD (1) DD273285A5 (ja)
DE (1) DE3854950D1 (ja)
DK (1) DK175468B1 (ja)
FI (1) FI103892B1 (ja)
HU (1) HUT52544A (ja)
IE (2) IE960853L (ja)
IL (1) IL85878A (ja)
NO (1) NO885275L (ja)
NZ (1) NZ224057A (ja)
PT (1) PT87083B (ja)
WO (1) WO1988007576A2 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
EP0330396B1 (en) * 1988-02-26 1995-06-21 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI
EP0339285A3 (en) * 1988-03-31 1989-11-29 RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) Recombinant endonexin ii
DE3910240A1 (de) * 1989-03-30 1990-10-04 Behringwerke Ag Pp4-delta, seine herstellung und verwendung
ATE89169T1 (de) * 1989-07-15 1993-05-15 Boehringer Ingelheim Int Antikoagulanz enthaltendes mittel.
DE3937607A1 (de) * 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
CA2070647C (en) * 1989-12-27 2001-04-10 Christiaan Reutelingsperger Use of an anticoagulant as a diagnostic agent
JPH05508664A (ja) * 1991-05-09 1993-12-02 ボード・オブ・リージェンツ・オブ・ザ・ユニヴァーシティ・オブ・ワシントン リン脂質標的血栓溶解剤
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
ES2146231T3 (es) * 1992-07-08 2000-08-01 Innogenetics Nv Polipeptidos derivados de la endonexina 2 y que presentan una actividad de receptor del virus de la hepatitis b, y su utilizacion en composiciones diagnosticas y farmaceuticas.
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US5767247A (en) * 1994-11-11 1998-06-16 Noboru Kaneko Anti-annexin-V monoclonal antibodies, and preparation and use thereof
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
ES2286247T3 (es) * 2001-02-21 2007-12-01 Alavita Pharmaceuticals, Inc. Proteinas anexinicas modificacdas y tratamiento de la trombosis.
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
CA2373468A1 (en) * 2001-03-16 2002-09-16 Ortho-Clinical Diagnostics, Inc. Reg-like protein
DE60236951D1 (de) * 2001-05-21 2010-08-19 Fujifilm Corp Vorrichtung zur Durchführung biochemischer Analysen und Verfahren zu ihrer Herstellung
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
FR2841557B1 (fr) * 2002-07-01 2005-12-09 Commissariat Energie Atomique Peptides ayant une affinite pour un phospholipide et utilisations
FR2841558B1 (fr) * 2002-07-01 2004-08-13 Commissariat Energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations
DE602004020855D1 (de) * 2003-11-20 2009-06-10 Hoffmann La Roche Spezifische Marker für Stoffwechselssyndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3438296A1 (de) * 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
US5066788A (en) * 1984-09-21 1991-11-19 Boehringer Ingelheim International Gmbh Blood coagulation inhibiting proteins, processes for preparing them and their uses
KR930007434B1 (ko) * 1984-09-21 1993-08-10 베링거 잉겔하임 인터내셔날 게엠베하 혈액응고 억제 단백질 제조방법
CN86100721A (zh) * 1985-01-10 1987-02-11 比奥根公司 为人类脂皮质激素多肽编码的脱氧核糖核酸顺序,含有它的重组脱氧核糖核酸分子及制造该多肽的方法
WO1986006100A1 (en) * 1985-04-15 1986-10-23 Biotechnology Research Partners, Limited Human anti-inflammatory phospholipase inhibitor protein
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
AU1299788A (en) * 1987-02-06 1988-08-24 Board Of Regents Of The University Of Washington, The Human proteins having anticoagulant and anti-inflammatory activity
US5179081A (en) * 1988-07-21 1993-01-12 Kowa Co., Ltd. Method of treatment using an anticoagulant polypeptide

Also Published As

Publication number Publication date
US5837842A (en) 1998-11-17
WO1988007576A2 (fr) 1988-10-06
FI103892B (fi) 1999-10-15
PT87083A (pt) 1988-04-01
EP0293567A1 (de) 1988-12-07
DK662288D0 (da) 1988-11-25
IL85878A0 (en) 1988-09-30
NO885275D0 (no) 1988-11-25
DK175468B1 (da) 2004-11-01
DK662288A (da) 1989-01-25
FI885504A0 (fi) 1988-11-28
JPH01503515A (ja) 1989-11-30
DE3854950D1 (de) 1996-03-14
IL85878A (en) 1993-07-08
NZ224057A (en) 1991-04-26
IE960853L (en) 1988-09-28
FI885504A (fi) 1988-11-28
ATE133707T1 (de) 1996-02-15
IE880928L (en) 1988-09-28
AU625214B2 (en) 1992-07-02
HUT52544A (en) 1990-07-28
NO885275L (no) 1989-01-25
AU1402788A (en) 1988-09-29
FI103892B1 (fi) 1999-10-15
WO1988007576A3 (fr) 1989-01-26
EP0293567B1 (de) 1996-01-31
KR890700666A (ko) 1989-11-26
PT87083B (pt) 1992-07-31
IE74679B1 (en) 1997-07-30

Similar Documents

Publication Publication Date Title
DD273285A5 (de) Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung
DE68910354T2 (de) Menschliches mutantes Angiogenin (Angiogenese-Faktor mit überlegener Angiogenin-Aktivität), Gene dafür und Methode zur Expression.
DE69018920T2 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
EP0168342B1 (de) Verfahren zur Herstellung von Thrombin-Inhibitoren
DE69024104T2 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
DE3650306T2 (de) Expressions- und Ausscheidungsvektoren für Hirudin mittels transformierter Hefe.
EP0769020B1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
DD296965A5 (de) Hefeverarbeitungssystem
DD299318A5 (de) Gereinigter ziliarer neurotrophischer faktor
DE3686399T2 (de) Herstellung von thrombin-inhibitoren.
DE3752008T2 (de) Hybride Plasminogenaktivatoren
DE69012377T2 (de) Polypeptid und dessen Herstellung.
DE3600571A1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel
DE3750379T3 (de) Varianten des abbaubeschleunigenden Faktors (DAF), hergestellt durch rekombinante DNS-Technologie.
DE3687948T2 (de) Verfahren und nukleinsaeure zur herstellung von lecithin: cholestrinacyltransferase.
DE3751081T2 (de) [Leu 13] Motilin, dessen kodierende DNS-Moleküle und Verfahren zu dessen Herstellung.
EP0677107B1 (de) Thrombininhibitor aus speichel von protostomiern
DE3724581A1 (de) Dna-sequenzen, die fuer proteine mit den biologischen eigenschaften des cystatin c codieren, herstellung dieser dna-sequenzen, expression des cystatin c sowie dieses enthaltende pharmazeutische zubereitungen
DD284045A5 (de) Verfahren zur herstellung von desulfarohirudinmutanten
DD274053A5 (de) Verfahren zur Produktion eines menschlichen, einkettigen Plasminogenaktivators
DE68923496T2 (de) Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression.
EP0244627A2 (de) Expressionsvektoren zur Gewinnung von Polypeptiden
DE3786870T2 (de) Methode zur Herstellung von Proteinen.
WO2002004486A2 (de) Bifunktionale fusionsproteine aus hirudin und tap
DE3737367A1 (de) Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee